Resona Asset Management Co. Ltd. Has $102.73 Million Position in Merck & Co., Inc. $MRK

Resona Asset Management Co. Ltd. cut its position in Merck & Co., Inc. (NYSE:MRK) by 1.7% in the 1st quarter, Holdings Channel.com reports. The firm owned 856,748 shares of the company’s stock after selling 14,931 shares during the period. Resona Asset Management Co. Ltd.’s holdings in Merck & Co., Inc. were worth $102,729,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in MRK. Chesapeake Wealth Management raised its holdings in Merck & Co., Inc. by 0.6% in the 4th quarter. Chesapeake Wealth Management now owns 14,740 shares of the company’s stock valued at $1,552,000 after buying an additional 87 shares during the last quarter. South Plains Financial Inc. boosted its position in Merck & Co., Inc. by 0.6% during the 4th quarter. South Plains Financial Inc. now owns 15,535 shares of the company’s stock worth $1,635,000 after buying an additional 89 shares during the period. Syverson Strege & Co grew its holdings in Merck & Co., Inc. by 2.2% during the 4th quarter. Syverson Strege & Co now owns 4,142 shares of the company’s stock worth $436,000 after acquiring an additional 90 shares during the last quarter. Nations Financial Group Inc. IA ADV grew its holdings in Merck & Co., Inc. by 0.4% during the 1st quarter. Nations Financial Group Inc. IA ADV now owns 23,433 shares of the company’s stock worth $2,819,000 after acquiring an additional 91 shares during the last quarter. Finally, Westside Investment Management Inc. increased its position in Merck & Co., Inc. by 3.1% in the 4th quarter. Westside Investment Management Inc. now owns 3,142 shares of the company’s stock valued at $331,000 after acquiring an additional 93 shares during the period. 76.07% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. Stock Performance

NYSE:MRK opened at $126.10 on Thursday. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. Merck & Co., Inc. has a fifty-two week low of $76.66 and a fifty-two week high of $130.29. The company has a 50 day simple moving average of $118.27 and a two-hundred day simple moving average of $116.06. The company has a market capitalization of $311.45 billion, a PE ratio of 35.52, a P/E/G ratio of 2.75 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The firm had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. During the same quarter in the previous year, the company earned $2.22 EPS. The company’s revenue for the quarter was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Research analysts anticipate that Merck & Co., Inc. will post 5.19 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, July 8th. Investors of record on Monday, June 15th were issued a $0.85 dividend. The ex-dividend date was Monday, June 15th. This represents a $3.40 annualized dividend and a yield of 2.7%. Merck & Co., Inc.’s payout ratio is presently 95.77%.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Royal Bank of Canada reaffirmed its outperform rating on Merck and set a $142 price target, signaling meaningful upside from current levels. Benzinga report on RBC rating
• Positive Sentiment: Wells Fargo raised its price target on Merck to $150 and kept an overweight rating, adding to the bullish analyst tone around the stock. Benzinga report on Wells Fargo price target
• Positive Sentiment: Merck’s recent KEYTRUDA approvals in breast and bladder cancer broaden the drug’s use in difficult-to-treat cancers and strengthen the company’s oncology franchise ahead of future exclusivity losses. Article on KEYTRUDA approvals
• Positive Sentiment: Merck also reached a new access agreement for its HIV treatment IDVYNSO, improving commercial access and adding another supportive development for the valuation story. Article on HIV access deal
• Neutral Sentiment: Merck is trading above both its 50-day and 200-day moving averages, which technically supports the stock, but the broader picture still includes patent expiry and vaccine-related concerns. Zacks technical analysis
• Neutral Sentiment: A separate research roundup highlighted Merck alongside other large-cap names, but did not introduce a new company-specific catalyst. Top Research Reports article
• Negative Sentiment: Some commentary noted Merck’s recent pullback and continuing investor focus on its post-Keytruda exclusivity outlook, which remains the main long-term risk to the stock. Article on valuation narrative

Analyst Ratings Changes

Several research firms have recently issued reports on MRK. Weiss Ratings downgraded shares of Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, May 15th. Zacks Research raised shares of Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 17th. CICC Research initiated coverage on Merck & Co., Inc. in a report on Wednesday, June 24th. They issued an “outperform” rating and a $138.00 price objective for the company. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $142.00 target price on shares of Merck & Co., Inc. in a research report on Wednesday. Finally, JPMorgan Chase & Co. lifted their target price on Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an “overweight” rating in a report on Monday, April 6th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and seven have issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $132.11.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.